Journal
CELLS
Volume 10, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/cells10040773
Keywords
warfarin; direct oral anticoagulants; vascular calcification; valvular calcification; vitamin K; matrix gla protein
Categories
Ask authors/readers for more resources
Warfarin has been used for anticoagulation for decades, but one of its lesser-known long-term side effects is an increase in systemic arterial calcification. Studies have shown that DOACs may have an advantage over warfarin in slowing the progression of vascular calcification, highlighting the potential benefits of DOACs in comparison.
Warfarin has been utilized for decades as an effective anticoagulant in patients with a history of strong risk factors for venous thromboembolism (VTE). Established adverse effects include bleeding, skin necrosis, teratogenicity during pregnancy, cholesterol embolization, and nephropathy. One of the lesser-known long-term side effects of warfarin is an increase in systemic arterial calcification. This is significant due to the association between vascular calcification and cardiovascular morbidity and mortality. Direct oral anticoagulants (DOACs) have gained prominence in recent years, as they require less frequent monitoring and have a superior side effect profile to warfarin, specifically in relation to major bleeding. The cost and lack of data for DOACs in some disease processes have precluded universal use. Within the last four years, retrospective cohort studies, observational studies, and randomized trials have shown, through different imaging modalities, that multiple DOACs are associated with slower progression of vascular calcification than warfarin. This review highlights the pathophysiology and mechanisms behind vascular calcification due to warfarin and compares the effect of warfarin and DOACs on systemic vasculature.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available